Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 777 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram Positive Bacterial Infection Clear all
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

NCT07573462
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
23
States / cities
Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 12:07 PM EDT
Recruiting Phase 4 Interventional

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

NCT05094570
View directory record Official record
Conditions
Nasal Polyps, Staphylococcus Aureus
Interventions
Dupilumab Prefilled Syringe
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 22, 2026, 12:07 PM EDT
Completed No phase listed Observational

Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis

NCT04024423
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterium Infection
Interventions
Epidemiologic investigation
Other
Lead sponsor
National Jewish Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects

NCT01828827
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824 1000 mg
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

NCT00096850
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Atazanavir, Rifampin, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
3
States / cities
Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652
View directory record Official record
Conditions
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 5 Years
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
21
States / cities
Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 4 Interventional

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

NCT03466502
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin
Drug
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 2 Interventional Results available

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

NCT00730028
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Trimethoprim-sulfamethoxazole, Placebo, Clindamycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 85 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 22, 2026, 12:07 PM EDT
Recruiting Not applicable Interventional

Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)

NCT07613645
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Health counseling sessions, Diet (control diet), Diet (experimental diet)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 12:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

NCT00859677
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 22, 2026, 12:07 PM EDT
Active, not recruiting Phase 2 Interventional

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

NCT02968212
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Clofazimine, sugar pill
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

NCT03835975
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
13vPnC, PPSV23, 20vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
875 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
34
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 22, 2026, 12:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?

NCT00756808
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
65 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT03788434
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 3 Interventional

Evaluation of Manufacturing Lot of StaphVAX

NCT00211900
View directory record Official record
Conditions
Staphylococcal Infections, Chronic Kidney Failure
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Madison, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax) Infection
Interventions
BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4, Control
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Miami, Florida • Raleigh, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 2 Interventional

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

NCT00144417
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin (with rifampin, pyrazinamide, and ethambutol), isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 22, 2026, 12:07 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of Mycobacterial Infections

NCT00018044
View directory record Official record
Conditions
Mycobacterium Infections
Interventions
Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT03950856
View directory record Official record
Conditions
Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
V114, Prevnar 13™
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
2,340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
30
States / cities
Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

NCT01265745
View directory record Official record
Conditions
Anthrax
Interventions
Normal Saline for Injection, MDX1303
Drug · Biological
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT02218372
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
Up to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers

NCT04204772
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
Activated charcoal and Tap Water, Activated Charcoal and Apple Juice
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 22, 2026, 12:07 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

NCT03595553
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 12:07 PM EDT